Comparing two types of engineered enzymes to treat psoriasis
Official title: Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis
Funded at University of Florida · NIH-11009926 · Data updated 2026-11-12
This study is looking at new ways to deliver special enzymes that can help calm down the immune system and reduce inflammation in people with psoriasis, a skin condition that can be really bothersome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | February 2, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $740,837 |
| NIH project number | 5R01AI171045-03 |
| Project ID | NIH-11009926 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with psoriasis or other related autoimmune conditions.
✕Less likely to help
Patients with psoriasis who are not responsive to immunotherapy or those with other unrelated skin conditions may not benefit from this research.
What this research studies
This research investigates innovative ways to administer engineered enzymes that can help redirect immune cells from causing chronic inflammation to restoring balance in the body. The study focuses on two forms of these enzymes: one that is anchored to tissues and another that circulates in the bloodstream. By examining how these different administration methods affect immune responses, the research aims to identify the most effective approach for treating psoriasis, a chronic autoimmune condition that can severely impact skin health.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from psoriasis, potentially improving their quality of life.
How similar studies have gone: Previous research has shown promise in using engineered enzymes for immune modulation, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Keselowsky, Benjamin George — University of Florida
- Study coordinator: Keselowsky, Benjamin George
Related research
Other NIH-funded projects on the same topics.
-
Testing antiplatelet approaches in psoriasis to improve blood vessel health
A study at NYU School of Medicine will test antiplatelet strategies to reduce heart and blood vessel risk in adults with psoriasis.
-
Topical immunoregulatory therapy for psoriasis
A new topical treatment for psoriasis is being developed to safely reduce skin symptoms and improve quality of life.
-
Understanding psoriasis genetic signals across diverse populations
A study to uncover the genetic factors behind psoriasis in African American people using advanced genomic and epigenetic methods.
-
SerpinB3 and keratinocytes: a new path to understanding psoriasis
This NIH grant explores how a keratinocyte protein called SerpinB3 may drive plaque psoriasis, with the hope of finding new treatments for people with moderate-to-severe disease.
-
Role of a skin protein in psoriasis-related diabetes
A study explores how a skin inflammation signal may contribute to developing type 2 diabetes in people with psoriasis.
-
How satisfied people with plaque psoriasis are with their treatments
This project will try a new questionnaire called DermSat to measure treatment satisfaction among people with plaque psoriasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.